AVI seeks orphan status for experimental SARS drug

By Staff Writers
Friday, 15 August, 2003

US firm Avi BioPharma has asked US regulators to grant 'orphan' status to its experimental drug against the virus that causes SARS, a designation meant to provide seven years of marketing exclusivity for medicines.

The Portland, Oregon-based drugmaker said it will seek the special status for its medicine, AVI-4179, based on positive pre-clinical data.

The US Food and Drug Administration grants orphan status to drugs for diseases that annually affect fewer than 200,000 Americans. The special designation is meant to encourage drug makers to develop products for rare or relatively uncommon ailments.

Related News

Newborns have elevated levels of an Alzheimer's biomarker

What do the brains of newborns and patients with Alzheimer's disease have in common? Both...

Cannabis use may double risk of cardiovascular disease death

Cannabis users have a 29% higher risk of acute coronary syndrome, a 20% higher risk of stroke,...

Space conditions can lead to periodontitis, scientists say

Living in zero gravity can lead to periodontitis — a serious condition where the gums...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd